Granite Bio, a Basel, Switzerland-based clinical-stage immunology company, raised $100M in funding.
The round consisted of a $30M Series A led by Versant Ventures and Novartis Venture Fund, and a $70M Series B led by Forbion and Sanofi Ventures.
The company intends to use the funds to expand operations and its R&D efforts.
Granite Bio is a biotechnology company developing antibodies that target the root causes of a variety of inflammatory, autoimmune and fibrotic conditions. Its pipeline features two first-in-class antibodies targeting multiple autoimmune diseases that address large market opportunities:
- GRT-001 depletes pro-inflammatory monocytes, key drivers of autoimmunity and inflammation. In non-human primate studies, GRT-001 efficiently and dose-dependently depleted pro-inflammatory monocytes. Treatment was well tolerated and spared tissue-resident macrophages, which are important for tissue homeostasis. GRT-001 is currently in Phase 1a testing in healthy volunteers and is expected to enter a Phase 1b trial in patients with inflammatory bowel disease later this year.
- GRT-002 blocks interleukin-3, a key player in autoimmune inflammation and type II inflammation, offering a new approach to treating itch and allergy. The molecule is in preclinical development and is expected to enter clinical trials in 2026.
The team includes:
- Patrick Loustau, president and CEO.
- Dominik Hartl, M.D., CMO.
- Gijs van den Brink, M.D., Ph.D., CSO.
- Eliot Forster, chairperson of the board.
FinSMEs
24/04/2025